Carmen Phillips
@carmenbphillips.bsky.social
Senior science writer at @SU2C & @SU2Cscience. Two decades of cancer communication under my belt and, if I have anything to do with it, more to come. Comments and opinions my own.
New study in @nature.com reveals mutational impact in normal tissue of things like smoking, drinking, & #cancer treatments. Median 25% of mutations caused by such "exogenous" factors. Smoking a doozy for the lungs: each pack year = 20 mutations per cell! www.nature.com/articles/s41...
Somatic evolution following cancer treatment in normal tissue - Nature
High-depth sequencing of non-cancerous tissue from patients with metastatic cancer reveals single-base mutational signatures of alcohol, smoking and cancer treatments, and reveals how exogenous factor...
www.nature.com
December 18, 2025 at 2:07 PM
New study in @nature.com reveals mutational impact in normal tissue of things like smoking, drinking, & #cancer treatments. Median 25% of mutations caused by such "exogenous" factors. Smoking a doozy for the lungs: each pack year = 20 mutations per cell! www.nature.com/articles/s41...
Reposted by Carmen Phillips
In this cohort study, most health-related social needs (HRSNs) were associated with ED visits, with strongest associations for housing instability and transportation. ja.ma/3N1MbSM
Health-Related Social Needs and Health Care Utilization
This cohort study of Medicare and Medicaid recipients examines the association of health-related social needs with inpatient and emergency department utilization and whether resolution of health-related social needs is associated with a reduction in utilization.
ja.ma
December 16, 2025 at 1:40 PM
In this cohort study, most health-related social needs (HRSNs) were associated with ED visits, with strongest associations for housing instability and transportation. ja.ma/3N1MbSM
Reposted by Carmen Phillips
In patients with HER2-positive early breast cancer and residual disease after neoadjuvant therapy, trastuzumab deruxtecan improved invasive disease–free survival but carried a risk of interstitial lung disease. Full DESTINY-Breast05 phase 3 trial results: nej.md/4an3Az2
December 10, 2025 at 7:05 PM
In patients with HER2-positive early breast cancer and residual disease after neoadjuvant therapy, trastuzumab deruxtecan improved invasive disease–free survival but carried a risk of interstitial lung disease. Full DESTINY-Breast05 phase 3 trial results: nej.md/4an3Az2
Particularly on the heels of the remarkable data out of Australia of ZERO cervical cancer dx in people <25 (in 2021), it's shocking to me that these findings on one dose of the #hpvvaccine haven't received more attention: www.nejm.org/doi/abs/10.1... #prevention #cancer
Noninferiority of One HPV Vaccine Dose to Two Doses | NEJM
Multidose human papillomavirus (HPV) vaccination is efficacious, yet the vaccine has
been underused globally. Emerging data suggest that a single dose may provide protection.
Whether a single dose ...
www.nejm.org
December 11, 2025 at 1:20 PM
Particularly on the heels of the remarkable data out of Australia of ZERO cervical cancer dx in people <25 (in 2021), it's shocking to me that these findings on one dose of the #hpvvaccine haven't received more attention: www.nejm.org/doi/abs/10.1... #prevention #cancer
Reposted by Carmen Phillips
Dr. Heather Landau, a cellular therapist at MSK, recently presented findings from a phase 1 clinical trial for patients with light chain (AL) amyloidosis with at the 2025 @ash.hematology.org Annual Meeting. #ASH25
bit.ly/4aBRoKM
bit.ly/4aBRoKM
December 8, 2025 at 7:59 PM
Dr. Heather Landau, a cellular therapist at MSK, recently presented findings from a phase 1 clinical trial for patients with light chain (AL) amyloidosis with at the 2025 @ash.hematology.org Annual Meeting. #ASH25
bit.ly/4aBRoKM
bit.ly/4aBRoKM
Reposted by Carmen Phillips
18% overall w/ G2+ LV systolic dysfunction. No sig benefit w/ ACEi before LV systolic dysfunction but possible protective effect w/ earlier initiation. (2/2) #ASH25
December 8, 2025 at 9:31 PM
18% overall w/ G2+ LV systolic dysfunction. No sig benefit w/ ACEi before LV systolic dysfunction but possible protective effect w/ earlier initiation. (2/2) #ASH25
Reposted by Carmen Phillips
A new clinical trial funded by @su2c.bsky.social and J&J for people with a difficult-to-treat disease called AL-amyloidosis. The trial, led by Dr. Suzanne Lentzsch of @columbiamed.bsky.social, will test the combination of (1/2) www.sciencedirect.com/science/arti...
Impact-AL: A phase 2 clinical trial of teclistamab and daratumumab in previously untreated AL amyloidosis
Background and Significance: Systemic immunoglobulin light chain (AL) amyloidosis remains a challenging disease, with current frontline regimens faili…
www.sciencedirect.com
December 8, 2025 at 7:58 PM
A new clinical trial funded by @su2c.bsky.social and J&J for people with a difficult-to-treat disease called AL-amyloidosis. The trial, led by Dr. Suzanne Lentzsch of @columbiamed.bsky.social, will test the combination of (1/2) www.sciencedirect.com/science/arti...